These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21032954)

  • 1. Inflammation, immune activation, and HIV.
    Highleyman L
    BETA; 2010; 22(2):12-26. PubMed ID: 21032954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paradox of the immune response in HIV infection: when inflammation becomes harmful.
    Ipp H; Zemlin A
    Clin Chim Acta; 2013 Feb; 416():96-9. PubMed ID: 23228847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune activation and inflammation in HIV-1 infection: causes and consequences.
    Appay V; Sauce D
    J Pathol; 2008 Jan; 214(2):231-41. PubMed ID: 18161758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation.
    Lane HC
    Top HIV Med; 2010; 18(1):2-6. PubMed ID: 20305309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflamed response: HIV provokes the immune system into a hyperactive state that can lead to chronic inflammation.
    Shepp DH
    Posit Aware; 2011; 23(5):14-7. PubMed ID: 22558842
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytokines: the magic is still there.
    Dumont FJ
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1092-4. PubMed ID: 16312128
    [No Abstract]   [Full Text] [Related]  

  • 7. Biomarkers and Clinical Indices of Aging with HIV.
    Fitch KV; Feldpausch MN; Looby SE
    Interdiscip Top Gerontol Geriatr; 2017; 42():47-58. PubMed ID: 27875823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring cellular immune markers in HIV infection: from activation to exhaustion.
    Sauce D; Elbim C; Appay V
    Curr Opin HIV AIDS; 2013 Mar; 8(2):125-31. PubMed ID: 23380653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.
    Lichtfuss GF; Hoy J; Rajasuriar R; Kramski M; Crowe SM; Lewin SR
    Biomark Med; 2011 Apr; 5(2):171-86. PubMed ID: 21473720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.
    Cohen DE; Walker BD
    Clin Infect Dis; 2001 Jun; 32(12):1756-68. PubMed ID: 11360218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenesis of HIV infection.
    Paranjape RS
    Indian J Med Res; 2005 Apr; 121(4):240-55. PubMed ID: 15817942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing HIV. Part 3: Mechanisms of disease. 3.3 How HIV leads to opportunistic infections.
    Crowe SM; Kornbluth RS
    Med J Aust; 1996 Feb; 164(3):171-3. PubMed ID: 8628138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics.
    Hummelen R; Vos AP; van't Land B; van Norren K; Reid G
    Int Rev Immunol; 2010 Oct; 29(5):485-513. PubMed ID: 20839912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglia as mediators of inflammatory and degenerative diseases.
    González-Scarano F; Baltuch G
    Annu Rev Neurosci; 1999; 22():219-40. PubMed ID: 10202538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated immune senescence and HIV-1 infection.
    Appay V; Almeida JR; Sauce D; Autran B; Papagno L
    Exp Gerontol; 2007 May; 42(5):432-7. PubMed ID: 17307327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV agents. Reduced inflammation linked to survival.
    TreatmentUpdate; 2009 Jan; 21(1):9-10. PubMed ID: 19248287
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing HIV. Part 3. Mechanisms of disease. 3.2 How HIV produces immune deficiency.
    Ffrench R; Stewart GJ; Penny R; Levy JA
    Med J Aust; 1996 Feb; 164(3):166-71. PubMed ID: 8628137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Premature aging in human immunodeficiency virus (HIV) infected patients: detection, pathophysiological mechanisms and management].
    Capeau J
    Bull Acad Natl Med; 2011 Dec; 195(9):2013-22; discussion 2022-4. PubMed ID: 22930865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.